Skip to main content
. 2022 Jan 13;8:786742. doi: 10.3389/fnut.2021.786742

Figure 3.

Figure 3

DFS and OS for the NRI of breast cancer patients in different molecular subtypes. (A) DFS and OS for the NRI of breast cancer patients in different molecular subtypes in all patients; (B) DFS and OS for the NRI of breast cancer patients in different molecular subtypes in NACT group; (C) DFS and OS for the NRI of breast cancer patients in different molecular subtypes in non-NACT group.